https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Lumateperone Submits Application for Schizophrenia Indication to FDA for Supplemental New Drug

Lumateperone Submits Application for Schizophrenia Indication to FDA for Supplemental New Drug

Lumatperone showed a 63% reduction in relapse risk for patients with schizophrenia, promising improved patient stability and care.

administrator

Related Articles